N Anthony Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CEREGet Free Report) Director N Anthony Coles sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $41.16, for a total transaction of $2,058,000.00. Following the completion of the transaction, the director now owns 15,638 shares in the company, valued at $643,660.08. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

N Anthony Coles also recently made the following trade(s):

  • On Wednesday, February 7th, N Anthony Coles sold 2,506 shares of Cerevel Therapeutics stock. The shares were sold at an average price of $41.54, for a total value of $104,099.24.

Cerevel Therapeutics Trading Up 0.1 %

CERE opened at $41.09 on Tuesday. Cerevel Therapeutics Holdings, Inc. has a one year low of $19.59 and a one year high of $43.59. The company has a market cap of $7.45 billion, a P/E ratio of -16.44 and a beta of 1.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 10.92 and a current ratio of 10.92. The business’s 50-day simple moving average is $42.06 and its 200-day simple moving average is $31.74.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright cut shares of Cerevel Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $41.00 to $45.00 in a report on Thursday, December 7th. Piper Sandler restated a “neutral” rating and issued a $45.00 price target (up previously from $33.00) on shares of Cerevel Therapeutics in a research note on Thursday, December 7th. Jefferies Financial Group reaffirmed a “hold” rating and set a $45.00 price objective (up previously from $40.00) on shares of Cerevel Therapeutics in a research report on Friday, December 22nd. Cantor Fitzgerald lowered Cerevel Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $38.00 to $45.00 in a report on Thursday, December 7th. Finally, Mizuho upped their price target on Cerevel Therapeutics from $25.00 to $45.00 and gave the stock a “neutral” rating in a report on Friday, February 16th. Nine analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cerevel Therapeutics presently has an average rating of “Hold” and a consensus target price of $39.64.

Get Our Latest Stock Analysis on CERE

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its position in shares of Cerevel Therapeutics by 3.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 517,244 shares of the biotechnology company’s stock valued at $11,291,000 after purchasing an additional 15,261 shares during the period. Citigroup Inc. boosted its position in shares of Cerevel Therapeutics by 22.7% in the 3rd quarter. Citigroup Inc. now owns 83,786 shares of the biotechnology company’s stock valued at $1,829,000 after purchasing an additional 15,507 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Cerevel Therapeutics by 19.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,079 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 1,925 shares during the period. Westfield Capital Management Co. LP boosted its position in shares of Cerevel Therapeutics by 69.3% in the 3rd quarter. Westfield Capital Management Co. LP now owns 974,483 shares of the biotechnology company’s stock valued at $21,273,000 after purchasing an additional 398,949 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Cerevel Therapeutics by 5.4% in the 2nd quarter. Rhumbline Advisers now owns 88,268 shares of the biotechnology company’s stock valued at $2,806,000 after purchasing an additional 4,546 shares during the period. Hedge funds and other institutional investors own 87.73% of the company’s stock.

About Cerevel Therapeutics

(Get Free Report)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.

See Also

Insider Buying and Selling by Quarter for Cerevel Therapeutics (NASDAQ:CERE)

Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.